GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution

[1]  Chieh-Yu Liu,et al.  IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution , 2014, American journal of hematology.

[2]  Chieh-Yu Liu,et al.  Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression , 2014, American journal of hematology.

[3]  B. Ko,et al.  Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome , 2014, Blood Cancer Journal.

[4]  Y. Hayashi,et al.  Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia , 2014, British journal of haematology.

[5]  S-J Wu,et al.  Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia , 2014, Leukemia.

[6]  J. Fitzgibbon,et al.  GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations , 2013, British journal of haematology.

[7]  A. Kohlmann,et al.  GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis , 2013, Leukemia.

[8]  E. Hoster,et al.  GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. , 2012, Blood.

[9]  Chieh-Yu Liu,et al.  DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. , 2012, Blood.

[10]  Chieh-Yu Liu,et al.  Clinical Trials and Observations , 2022 .

[11]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[12]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[13]  B. Ko,et al.  The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia , 2011, Leukemia.

[14]  B. Ko,et al.  Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. , 2010, Blood.

[15]  Chieh-Yu Liu,et al.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. , 2010, Blood.

[16]  O. Haas,et al.  Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Arceci.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system , 2010 .

[18]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[19]  H. Tien,et al.  Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD , 2008, Leukemia.

[20]  Saijuan Chen,et al.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia , 2008, Proceedings of the National Academy of Sciences.

[21]  B. Ko,et al.  RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.

[22]  R. Arceci,et al.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. , 2007, The oncologist.

[23]  B. Ko,et al.  Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome , 2006, Leukemia.

[24]  M. Yao,et al.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.

[25]  Jih-Luh Tang,et al.  Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells , 2005, Clinical Cancer Research.

[26]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[27]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Yao,et al.  Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23 , 2002, Leukemia.

[29]  S. Orkin,et al.  Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. , 1997, Blood.

[30]  Y C Chen,et al.  Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. , 1995, Cancer genetics and cytogenetics.

[31]  Stuart H. Orkin,et al.  An early haematopoietic defect in mice lacking the transcription factor GATA-2 , 1994, Nature.